Home > Dermatology > SPIN 2022 > Psoriasis: The Beat Goes On > Paediatric psoriasis: ixekizumab beneficial in difficult-to-treat areas

Paediatric psoriasis: ixekizumab beneficial in difficult-to-treat areas

Presented By
Dr Marieke Seyger , Radboud University Medical Centre, the Netherlands
Conference
SPIN 2022
Trial
Phase 3, IXORA-PEDS
Doi
https://doi.org/10.55788/009fbd72
High clearance rates in challenging body areas of children were observed on long-term ixekizumab treatment for psoriasis. After 108 weeks, scalp psoriasis, for example, was cleared in 76.2% and genital psoriasis in 87.5% of patients. Psoriasis involving certain difficult-to-treat areas of the body can account for a more substantial impact on quality-of-life than might be expected from just looking at the surface area involved [1]. Thus, an international group with primary investigator Dr Marieke Seyger (Radboud University Medical Centre, the Netherlands) focussed on the long-term efficacy of ixekizumab in children and adolescents with moderate-to-severe psoriasis, especially in these areas [2]. They presented data from the phase 3 IXORA-PEDS trial (NCT03073200) and its open-label extension until week 108. Of the 171 participants randomised in the placebo-con...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on